Human medicines
The Estonian human medicinal products market was 153 million euros in wholesale prices in the fourth quarter of 2025. Compared to the same period of the previous year, the turnover increased 7%. The market of human medicines by quarter during last five years is on Figure 1.
Figure 1. Human medicinal products market by quarters, in 2021–2025.
During Q4 2025 there were 25 licensed medicinal product wholesalers, who distributed human medicines to general or hospital pharmacies or to other institutions in Estonia. Sales to general pharmacies covered 73.4%, sales to hospital pharmacies 25.4% and sales to other institutions 1.2% of total medicinal products market.
The sales of prescription medicines covered 89% and the sales of over-the-counter medicines 11% of the pharmaceutical market.
The most used medicines by DDD/1000/day were cardiovascular system medicines (592 DDD/1000/day), followed by alimentary tract and metabolism medicines (256 DDD/1000/day) and nervous system medicines (199 DDD/1000/day). These three ATC groups covered 67% of overall medicines consumption in Estonia in Q4 2025.
Altogether 1361 different active substances were marketed and the most used active substances were Rosuvastatin (87 DDD/1000/day), Ramipril (58 DDD/1000/day), and Atorvastatin (58 DDD/1000/day).
The most sold medicines by turnover were antineoplastic and immunomodulating agents (38 million euros), alimentary tract and metabolism medicines (26 million euros) and medicines for nervous system (16 million euros). The market share of these three ATC groups was altogether 52%
Human medicines IV quarter 2025 in summary:
- Medicinal products market: 153 million euros
- Sales to pharmacies: 113 million euros
- Sales to hospital pharmacies: 39 million euros
- Sales to other institutions: 2 million euros
- Antineoplastic and immunomodulating agents: 38 million euros
- Alimentary tract and metabolism: 26 million euros
- Medicines for nervous system:16 million euros
Veterinary medicines
The Estonian veterinary medicinal products market was 4.8 million euros in wholesale prices in the fourth quarter of 2025. Compared to the same period of the previous year the turnover increased 4%. From the overall sales, 95% of veterinary medicines were sold to the veterinarians or to the agricultural companies represented by a veterinarian, and 5% to the general and veterinary pharmacies.
Figure 2. Veterinary medicinal products market (medicines used in animals) by quarters, in 2021–2025
The most sold medicines by turnover were immunologicals, followed by antiparasitic products and antiinfectives for systemic use, accounting for 24%, 19% and 18% of total veterinary medicines sales, respectively.
Veterinary medicines IV quarter 2025 in summary:
- Veterinary medicinal products market: 4.8 mil euros
- Sales to veterinarians: 4.6 mil euros
- Sales to general and veterinary pharmacies: 0.2 mil euros
- Immunologicals (QI): 1.1 mil euros
- Antiparasitic products (QP): 0.9 mil euros
- Antiinfectives for systemic use (QJ): 0.8 mil euros
